Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

Rev Esp Cardiol (Engl Ed). 2016 Dec;69(12):1119-1125. doi: 10.1016/j.rec.2016.10.015.
[Article in English, Spanish]
No abstract available

Publication types

  • Editorial

MeSH terms

  • Acute Disease
  • Adrenergic beta-Antagonists / therapeutic use
  • Algorithms*
  • Aminobutyrates / therapeutic use
  • Angiotensin Receptor Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Benzazepines / therapeutic use
  • Biphenyl Compounds
  • Cardiac Resynchronization Therapy*
  • Cardiovascular Agents / therapeutic use*
  • Chronic Disease
  • Death, Sudden, Cardiac / prevention & control*
  • Defibrillators, Implantable*
  • Drug Combinations
  • Early Medical Intervention
  • Echocardiography
  • Europe
  • Extracorporeal Membrane Oxygenation*
  • Heart Failure / blood
  • Heart Failure / diagnosis
  • Heart Failure / therapy*
  • Humans
  • Ivabradine
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Natriuretic Peptides / blood
  • Practice Guidelines as Topic*
  • Spain
  • Stroke Volume
  • Tetrazoles / therapeutic use
  • Valsartan

Substances

  • Adrenergic beta-Antagonists
  • Aminobutyrates
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Benzazepines
  • Biphenyl Compounds
  • Cardiovascular Agents
  • Drug Combinations
  • Mineralocorticoid Receptor Antagonists
  • Natriuretic Peptides
  • Tetrazoles
  • Ivabradine
  • Valsartan
  • sacubitril and valsartan sodium hydrate drug combination